| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | galactoside 2-alpha-L-fucosyltransferase activity | 1.06e-05 | 3 | 38 | 2 | GO:0008107 | |
| GeneOntologyMolecularFunction | alpha-(1,2)-fucosyltransferase activity | 1.06e-05 | 3 | 38 | 2 | GO:0031127 | |
| GeneOntologyMolecularFunction | ATP:phosphate antiporter activity | 1.06e-05 | 3 | 38 | 2 | GO:0140987 | |
| GeneOntologyMolecularFunction | acetyltransferase activity | 4.47e-05 | 104 | 38 | 4 | GO:0016407 | |
| GeneOntologyMolecularFunction | organophosphate:phosphate antiporter activity | 7.36e-05 | 7 | 38 | 2 | GO:0015315 | |
| GeneOntologyMolecularFunction | cytoskeletal protein binding | 1.72e-04 | 1099 | 38 | 9 | GO:0008092 | |
| GeneOntologyMolecularFunction | store-operated calcium channel activity | 2.30e-04 | 12 | 38 | 2 | GO:0015279 | |
| GeneOntologyMolecularFunction | inositol 1,4,5 trisphosphate binding | 3.16e-04 | 14 | 38 | 2 | GO:0070679 | |
| GeneOntologyMolecularFunction | ATP transmembrane transporter activity | 3.16e-04 | 14 | 38 | 2 | GO:0005347 | |
| GeneOntologyMolecularFunction | fucosyltransferase activity | 3.16e-04 | 14 | 38 | 2 | GO:0008417 | |
| GeneOntologyMolecularFunction | histone H3 acetyltransferase activity | 3.65e-04 | 15 | 38 | 2 | GO:0010484 | |
| GeneOntologyMolecularFunction | protein antigen binding | 4.16e-04 | 16 | 38 | 2 | GO:1990405 | |
| GeneOntologyMolecularFunction | purine ribonucleotide transmembrane transporter activity | 8.70e-04 | 23 | 38 | 2 | GO:0005346 | |
| GeneOntologyMolecularFunction | histone H4 acetyltransferase activity | 8.70e-04 | 23 | 38 | 2 | GO:0010485 | |
| GeneOntologyMolecularFunction | phosphate transmembrane transporter activity | 9.48e-04 | 24 | 38 | 2 | GO:0005315 | |
| GeneOntologyMolecularFunction | acyltransferase activity, transferring groups other than amino-acyl groups | 1.06e-03 | 238 | 38 | 4 | GO:0016747 | |
| GeneOntologyMolecularFunction | adenine nucleotide transmembrane transporter activity | 1.11e-03 | 26 | 38 | 2 | GO:0000295 | |
| GeneOntologyMolecularFunction | purine nucleotide transmembrane transporter activity | 1.39e-03 | 29 | 38 | 2 | GO:0015216 | |
| GeneOntologyMolecularFunction | cytoskeletal motor activity | 1.46e-03 | 118 | 38 | 3 | GO:0003774 | |
| GeneOntologyMolecularFunction | solute:inorganic anion antiporter activity | 1.69e-03 | 32 | 38 | 2 | GO:0005452 | |
| GeneOntologyMolecularFunction | nucleotide transmembrane transporter activity | 1.79e-03 | 33 | 38 | 2 | GO:0015215 | |
| GeneOntologyMolecularFunction | organophosphate ester transmembrane transporter activity | 2.50e-03 | 39 | 38 | 2 | GO:0015605 | |
| GeneOntologyMolecularFunction | histone acetyltransferase activity | 4.24e-03 | 51 | 38 | 2 | GO:0004402 | |
| GeneOntologyMolecularFunction | peptide-lysine-N-acetyltransferase activity | 4.91e-03 | 55 | 38 | 2 | GO:0061733 | |
| GeneOntologyMolecularFunction | O-acyltransferase activity | 5.64e-03 | 59 | 38 | 2 | GO:0008374 | |
| GeneOntologyMolecularFunction | carbohydrate derivative transmembrane transporter activity | 5.64e-03 | 59 | 38 | 2 | GO:1901505 | |
| GeneOntologyMolecularFunction | nucleobase-containing compound transmembrane transporter activity | 5.64e-03 | 59 | 38 | 2 | GO:0015932 | |
| GeneOntologyMolecularFunction | peptide N-acetyltransferase activity | 5.82e-03 | 60 | 38 | 2 | GO:0034212 | |
| GeneOntologyMolecularFunction | microtubule motor activity | 7.85e-03 | 70 | 38 | 2 | GO:0003777 | |
| GeneOntologyMolecularFunction | histone modifying activity | 9.35e-03 | 229 | 38 | 3 | GO:0140993 | |
| GeneOntologyMolecularFunction | N-acetyltransferase activity | 9.67e-03 | 78 | 38 | 2 | GO:0008080 | |
| GeneOntologyMolecularFunction | myosin binding | 1.14e-02 | 85 | 38 | 2 | GO:0017022 | |
| GeneOntologyMolecularFunction | inorganic molecular entity transmembrane transporter activity | 1.38e-02 | 758 | 38 | 5 | GO:0015318 | |
| GeneOntologyMolecularFunction | acyltransferase activity | 1.51e-02 | 775 | 38 | 5 | GO:0016746 | |
| GeneOntologyBiologicalProcess | mesenchyme migration | 5.75e-08 | 5 | 38 | 3 | GO:0090131 | |
| GeneOntologyBiologicalProcess | skeletal muscle thin filament assembly | 6.90e-05 | 7 | 38 | 2 | GO:0030240 | |
| GeneOntologyBiologicalProcess | fucose catabolic process | 1.18e-04 | 9 | 38 | 2 | GO:0019317 | |
| GeneOntologyBiologicalProcess | L-fucose catabolic process | 1.18e-04 | 9 | 38 | 2 | GO:0042355 | |
| GeneOntologyBiologicalProcess | L-fucose metabolic process | 1.47e-04 | 10 | 38 | 2 | GO:0042354 | |
| GeneOntologyBiologicalProcess | skeletal myofibril assembly | 1.80e-04 | 11 | 38 | 2 | GO:0014866 | |
| GeneOntologyBiologicalProcess | ADP transport | 2.16e-04 | 12 | 38 | 2 | GO:0015866 | |
| GeneOntologyBiologicalProcess | organophosphate ester transport | 2.20e-04 | 162 | 38 | 4 | GO:0015748 | |
| GeneOntologyBiologicalProcess | mesenchyme morphogenesis | 2.33e-04 | 65 | 38 | 3 | GO:0072132 | |
| GeneOntologyBiologicalProcess | oligosaccharide metabolic process | 2.90e-04 | 70 | 38 | 3 | GO:0009311 | |
| GeneOntologyBiologicalProcess | fucose metabolic process | 3.90e-04 | 16 | 38 | 2 | GO:0006004 | |
| GeneOntologyBiologicalProcess | regulation of cellular response to heat | 3.90e-04 | 16 | 38 | 2 | GO:1900034 | |
| GeneOntologyCellularComponent | microtubule organizing center attachment site | 1.75e-04 | 11 | 38 | 2 | GO:0034992 | |
| GeneOntologyCellularComponent | nuclear membrane protein complex | 1.75e-04 | 11 | 38 | 2 | GO:0106083 | |
| GeneOntologyCellularComponent | nuclear membrane microtubule tethering complex | 1.75e-04 | 11 | 38 | 2 | GO:0106094 | |
| GeneOntologyCellularComponent | meiotic nuclear membrane microtubule tethering complex | 1.75e-04 | 11 | 38 | 2 | GO:0034993 | |
| GeneOntologyCellularComponent | histone acetyltransferase complex | 6.63e-04 | 94 | 38 | 3 | GO:0000123 | |
| GeneOntologyCellularComponent | lamellipodium | 7.86e-04 | 230 | 38 | 4 | GO:0030027 | |
| GeneOntologyCellularComponent | DNA repair complex | 7.95e-04 | 23 | 38 | 2 | GO:1990391 | |
| GeneOntologyCellularComponent | protein acetyltransferase complex | 8.89e-04 | 104 | 38 | 3 | GO:0031248 | |
| GeneOntologyCellularComponent | acetyltransferase complex | 1.02e-03 | 109 | 38 | 3 | GO:1902493 | |
| GeneOntologyCellularComponent | filopodium | 1.44e-03 | 123 | 38 | 3 | GO:0030175 | |
| GeneOntologyCellularComponent | H4/H2A histone acetyltransferase complex | 1.54e-03 | 32 | 38 | 2 | GO:0043189 | |
| GeneOntologyCellularComponent | NuA4 histone acetyltransferase complex | 1.54e-03 | 32 | 38 | 2 | GO:0035267 | |
| GeneOntologyCellularComponent | intracellular protein-containing complex | 1.64e-03 | 972 | 38 | 7 | GO:0140535 | |
| GeneOntologyCellularComponent | contractile muscle fiber | 1.85e-03 | 290 | 38 | 4 | GO:0043292 | |
| GeneOntologyCellularComponent | actin filament | 2.35e-03 | 146 | 38 | 3 | GO:0005884 | |
| GeneOntologyCellularComponent | nuclear outer membrane | 2.40e-03 | 40 | 38 | 2 | GO:0005640 | |
| GeneOntologyCellularComponent | H4 histone acetyltransferase complex | 3.03e-03 | 45 | 38 | 2 | GO:1902562 | |
| GeneOntologyCellularComponent | nuclear ubiquitin ligase complex | 3.59e-03 | 49 | 38 | 2 | GO:0000152 | |
| HumanPheno | Dyspnea | 1.57e-05 | 506 | 14 | 8 | HP:0002094 | |
| HumanPheno | Respiratory insufficiency | 2.64e-05 | 962 | 14 | 10 | HP:0002093 | |
| HumanPheno | Abnormal cardiac ventricle morphology | 4.29e-05 | 780 | 14 | 9 | HP:0001713 | |
| HumanPheno | Cardiac conduction abnormality | 5.62e-05 | 167 | 14 | 5 | HP:0031546 | |
| HumanPheno | Abnormal thorax morphology | 5.93e-05 | 1328 | 14 | 11 | HP:0000765 | |
| HumanPheno | Lower extremity joint dislocation | 1.11e-04 | 318 | 14 | 6 | HP:0030311 | |
| HumanPheno | Neoplasm of the stomach | 1.11e-04 | 98 | 14 | 4 | HP:0006753 | |
| HumanPheno | Cerebral hemorrhage | 1.35e-04 | 103 | 14 | 4 | HP:0001342 | |
| HumanPheno | Respiratory insufficiency due to muscle weakness | 1.35e-04 | 103 | 14 | 4 | HP:0002747 | |
| HumanPheno | Benign neoplasm of the central nervous system | 1.46e-04 | 105 | 14 | 4 | HP:0100835 | |
| HumanPheno | Abnormality of blood circulation | 1.52e-04 | 498 | 14 | 7 | HP:0011028 | |
| HumanPheno | Internal hemorrhage | 1.58e-04 | 339 | 14 | 6 | HP:0011029 | |
| HumanPheno | Neoplasm of the large intestine | 2.00e-04 | 114 | 14 | 4 | HP:0100834 | |
| HumanPheno | Weakness of muscles of respiration | 2.14e-04 | 116 | 14 | 4 | HP:0004347 | |
| HumanPheno | Neoplasm of the rectum | 2.34e-04 | 46 | 14 | 3 | HP:0100743 | |
| HumanPheno | Respiratory distress | 2.37e-04 | 226 | 14 | 5 | HP:0002098 | |
| HumanPheno | Lipodystrophy | 3.04e-04 | 127 | 14 | 4 | HP:0009125 | |
| HumanPheno | Abnormal cerebral vascular morphology | 3.33e-04 | 388 | 14 | 6 | HP:0100659 | |
| HumanPheno | Joint dislocation | 3.43e-04 | 390 | 14 | 6 | HP:0001373 | |
| HumanPheno | Generalized muscle weakness | 3.73e-04 | 134 | 14 | 4 | HP:0003324 | |
| HumanPheno | Abnormal muscle tissue metabolite concentration | 3.77e-04 | 54 | 14 | 3 | HP:0034370 | |
| HumanPheno | Abnormal circulating creatine concentration | 3.80e-04 | 11 | 14 | 2 | HP:0012113 | |
| HumanPheno | Abnormal subclavian artery morphology | 3.80e-04 | 11 | 14 | 2 | HP:0031251 | |
| HumanPheno | Renal neoplasm | 4.30e-04 | 139 | 14 | 4 | HP:0009726 | |
| HumanPheno | Increased overbite | 4.56e-04 | 12 | 14 | 2 | HP:0011094 | |
| HumanPheno | Feeding difficulties in infancy | 4.65e-04 | 594 | 14 | 7 | HP:0008872 | |
| HumanPheno | Spinal rigidity | 4.91e-04 | 59 | 14 | 3 | HP:0003306 | |
| HumanPheno | Urinary tract neoplasm | 4.92e-04 | 144 | 14 | 4 | HP:0010786 | |
| HumanPheno | Flexion contracture | 5.14e-04 | 817 | 14 | 8 | HP:0001371 | |
| HumanPheno | Joint contracture | 6.41e-04 | 843 | 14 | 8 | HP:0034392 | |
| HumanPheno | Abnormal left ventricular function | 6.50e-04 | 155 | 14 | 4 | HP:0005162 | |
| HumanPheno | Low weight | 6.51e-04 | 627 | 14 | 7 | HP:0001823 | |
| HumanPheno | Intracranial hemorrhage | 6.66e-04 | 156 | 14 | 4 | HP:0002170 | |
| HumanPheno | Exercise intolerance | 6.66e-04 | 156 | 14 | 4 | HP:0003546 | |
| HumanPheno | Muscle fiber atrophy | 7.14e-04 | 67 | 14 | 3 | HP:0100295 | |
| HumanPheno | Hypertrophic cardiomyopathy | 7.55e-04 | 290 | 14 | 5 | HP:0001639 | |
| HumanPheno | EMG abnormality | 7.92e-04 | 293 | 14 | 5 | HP:0003457 | |
| HumanPheno | Abnormal pattern of respiration | 8.12e-04 | 872 | 14 | 8 | HP:0002793 | |
| HumanPheno | Abnormal tendon morphology | 8.32e-04 | 875 | 14 | 8 | HP:0100261 | |
| HumanPheno | Uterine neoplasm | 8.81e-04 | 72 | 14 | 3 | HP:0010784 | |
| HumanPheno | Abnormal muscle fiber morphology | 9.09e-04 | 302 | 14 | 5 | HP:0004303 | |
| HumanPheno | Limb-girdle muscular dystrophy | 9.32e-04 | 17 | 14 | 2 | HP:0006785 | |
| HumanPheno | Mild microcephaly | 9.32e-04 | 17 | 14 | 2 | HP:0040196 | |
| HumanPheno | Hyperintensity of cerebral white matter on MRI | 9.55e-04 | 74 | 14 | 3 | HP:0030890 | |
| HumanPheno | Adult onset | 9.66e-04 | 894 | 14 | 8 | HP:0003581 | |
| HumanPheno | Abnormal cardiac ventricular function | 9.85e-04 | 173 | 14 | 4 | HP:0030872 | |
| HumanPheno | Abnormal sternum morphology | 9.86e-04 | 474 | 14 | 6 | HP:0000766 | |
| HumanPheno | Female reproductive system neoplasm | 1.03e-03 | 76 | 14 | 3 | HP:0033020 | |
| HumanPheno | Cardiac diverticulum | 1.05e-03 | 18 | 14 | 2 | HP:0100571 | |
| HumanPheno | Type 1 muscle fiber atrophy | 1.05e-03 | 18 | 14 | 2 | HP:0011807 | |
| HumanPheno | Neoplasm of the central nervous system | 1.10e-03 | 178 | 14 | 4 | HP:0100006 | |
| HumanPheno | Left ventricular noncompaction | 1.17e-03 | 19 | 14 | 2 | HP:0030682 | |
| HumanPheno | Abnormal morphology of left ventricular trabeculae | 1.17e-03 | 19 | 14 | 2 | HP:0031192 | |
| HumanPheno | Dilated cardiomyopathy | 1.24e-03 | 184 | 14 | 4 | HP:0001644 | |
| HumanPheno | Abnormal heart morphology | 1.24e-03 | 184 | 14 | 4 | HP:3000001 | |
| HumanPheno | Neoplasm of the colon | 1.24e-03 | 81 | 14 | 3 | HP:0100273 | |
| HumanPheno | Abnormal morphology of myocardial trabeculae | 1.30e-03 | 20 | 14 | 2 | HP:0030681 | |
| HumanPheno | Abnormality of the amniotic fluid | 1.37e-03 | 504 | 14 | 6 | HP:0001560 | |
| HumanPheno | Congenital hip dislocation | 1.38e-03 | 84 | 14 | 3 | HP:0001374 | |
| HumanPheno | Clumsiness | 1.48e-03 | 86 | 14 | 3 | HP:0002312 | |
| HumanPheno | Neoplasm of the nervous system | 1.54e-03 | 195 | 14 | 4 | HP:0004375 | |
| HumanPheno | Proximal muscle weakness | 1.56e-03 | 340 | 14 | 5 | HP:0003701 | |
| HumanPheno | Fatiguable weakness of proximal limb muscles | 1.57e-03 | 22 | 14 | 2 | HP:0030200 | |
| HumanPheno | Myopathy | 1.58e-03 | 341 | 14 | 5 | HP:0003198 | |
| MousePheno | early cellular replicative senescence | 1.86e-05 | 70 | 32 | 4 | MP:0008008 | |
| MousePheno | abnormal cellular replicative senescence | 3.17e-05 | 80 | 32 | 4 | MP:0008007 | |
| MousePheno | abnormal skeletal muscle fiber morphology | 1.10e-04 | 212 | 32 | 5 | MP:0003084 | |
| MousePheno | ovary degeneration | 1.81e-04 | 9 | 32 | 2 | MP:0013236 | |
| MousePheno | abnormal muscle physiology | 2.07e-04 | 954 | 32 | 9 | MP:0002106 | |
| MousePheno | abnormal muscle fiber morphology | 2.76e-04 | 406 | 32 | 6 | MP:0004087 | |
| Domain | Actin_CS | 2.60e-08 | 16 | 38 | 4 | IPR004001 | |
| Domain | ACTINS_2 | 3.40e-08 | 17 | 38 | 4 | PS00432 | |
| Domain | Actin/actin-like_CS | 4.37e-08 | 18 | 38 | 4 | IPR020902 | |
| Domain | ACTINS_ACT_LIKE | 5.52e-08 | 19 | 38 | 4 | PS01132 | |
| Domain | ACTINS_1 | 4.32e-07 | 8 | 38 | 3 | PS00406 | |
| Domain | Actin | 4.41e-07 | 31 | 38 | 4 | IPR004000 | |
| Domain | Actin | 4.41e-07 | 31 | 38 | 4 | PF00022 | |
| Domain | ACTIN | 4.41e-07 | 31 | 38 | 4 | SM00268 | |
| Domain | Glyco_trans_11 | 4.03e-06 | 2 | 38 | 2 | IPR002516 | |
| Domain | Glyco_transf_11 | 4.03e-06 | 2 | 38 | 2 | PF01531 | |
| Domain | TRP_dom | 6.02e-05 | 6 | 38 | 2 | IPR013555 | |
| Domain | TRP_2 | 6.02e-05 | 6 | 38 | 2 | PF08344 | |
| Domain | TRPC_channel | 8.41e-05 | 7 | 38 | 2 | IPR002153 | |
| Domain | TRP_channel | 2.19e-04 | 11 | 38 | 2 | IPR004729 | |
| Domain | Actinin_actin-bd_CS | 9.93e-04 | 23 | 38 | 2 | IPR001589 | |
| Domain | - | 9.93e-04 | 23 | 38 | 2 | 3.30.530.20 | |
| Domain | ACTININ_2 | 9.93e-04 | 23 | 38 | 2 | PS00020 | |
| Domain | ACTININ_1 | 9.93e-04 | 23 | 38 | 2 | PS00019 | |
| Domain | START-like_dom | 9.93e-04 | 23 | 38 | 2 | IPR023393 | |
| Domain | HR1_rho-bd | 1.17e-03 | 25 | 38 | 2 | IPR011072 | |
| Domain | Mit_carrier | 1.92e-03 | 32 | 38 | 2 | IPR002067 | |
| Domain | SOLCAR | 5.20e-03 | 53 | 38 | 2 | PS50920 | |
| Domain | Mito_carr | 5.20e-03 | 53 | 38 | 2 | PF00153 | |
| Domain | - | 5.20e-03 | 53 | 38 | 2 | 1.50.40.10 | |
| Domain | Mt_carrier_dom | 5.20e-03 | 53 | 38 | 2 | IPR023395 | |
| Domain | Mitochondrial_sb/sol_carrier | 5.20e-03 | 53 | 38 | 2 | IPR018108 | |
| Domain | CH | 7.73e-03 | 65 | 38 | 2 | SM00033 | |
| Pathway | WP_STRIATED_MUSCLE_CONTRACTION_PATHWAY | 3.52e-05 | 38 | 24 | 3 | M39549 | |
| Pathway | WP_LACTO_SERIES_SPHINGOLIPID_METABOLISM | 4.15e-05 | 6 | 24 | 2 | M46444 | |
| Pathway | WP_MECHANOREGULATION_AND_PATHOLOGY_OF_YAPTAZ_VIA_HIPPO_AND_NONHIPPO_MECHANISMS | 6.69e-05 | 47 | 24 | 3 | M39829 | |
| Pathway | REACTOME_ROLE_OF_SECOND_MESSENGERS_IN_NETRIN_1_SIGNALING | 1.24e-04 | 10 | 24 | 2 | M27330 | |
| Pathway | WP_NEOLACTO_SERIES_SPHINGOLIPID_METABOLISM | 1.51e-04 | 11 | 24 | 2 | M48314 | |
| Pathway | WP_HOMOLOGOUS_RECOMBINATION | 1.81e-04 | 12 | 24 | 2 | MM15951 | |
| Pathway | WP_UROTENSINIIMEDIATED_SIGNALING | 2.11e-04 | 69 | 24 | 3 | M48052 | |
| Pathway | WP_HOMOLOGOUS_RECOMBINATION | 2.14e-04 | 13 | 24 | 2 | M39712 | |
| Pathway | KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_GLOBO_SERIES | 2.50e-04 | 14 | 24 | 2 | M12899 | |
| Pathway | KEGG_MEDICUS_REFERENCE_P300_P21_CELL_CYCLE_G1_S | 2.88e-04 | 15 | 24 | 2 | M47524 | |
| Pathway | BIOCARTA_RACC_PATHWAY | 2.88e-04 | 15 | 24 | 2 | M22002 | |
| Pathway | WP_FAMILIAL_HYPERLIPIDEMIA_TYPE_5 | 2.88e-04 | 15 | 24 | 2 | M42552 | |
| Pathway | WP_GLIOBLASTOMA_SIGNALING | 3.64e-04 | 83 | 24 | 3 | M39637 | |
| Pathway | REACTOME_BLOOD_GROUP_SYSTEMS_BIOSYNTHESIS | 3.72e-04 | 17 | 24 | 2 | MM15629 | |
| Pathway | REACTOME_REGULATION_OF_TP53_ACTIVITY_THROUGH_METHYLATION | 4.18e-04 | 18 | 24 | 2 | MM15342 | |
| Pathway | WP_FAMILIAL_HYPERLIPIDEMIA_TYPE_1 | 4.18e-04 | 18 | 24 | 2 | M42559 | |
| Pathway | REACTOME_GLYCOSPHINGOLIPID_BIOSYNTHESIS | 4.67e-04 | 19 | 24 | 2 | MM17075 | |
| Pathway | REACTOME_REGULATION_OF_TP53_ACTIVITY_THROUGH_METHYLATION | 4.67e-04 | 19 | 24 | 2 | M27639 | |
| Pathway | REACTOME_GLYCOSPHINGOLIPID_BIOSYNTHESIS | 4.67e-04 | 19 | 24 | 2 | M48041 | |
| Pathway | REACTOME_NOTCH4_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 5.18e-04 | 20 | 24 | 2 | M27881 | |
| Pathway | WP_HEMATOPOIETIC_STEM_CELL_GENE_REGULATION_BY_GABP_ALPHABETA_COMPLEX | 5.72e-04 | 21 | 24 | 2 | M39593 | |
| Pathway | BIOCARTA_P53HYPOXIA_PATHWAY | 5.72e-04 | 21 | 24 | 2 | M5202 | |
| Pathway | REACTOME_BLOOD_GROUP_SYSTEMS_BIOSYNTHESIS | 5.72e-04 | 21 | 24 | 2 | M27917 | |
| Pathway | BIOCARTA_ATRBRCA_PATHWAY | 6.28e-04 | 22 | 24 | 2 | M9703 | |
| Pathway | WP_FAMILIAL_HYPERLIPIDEMIA_TYPE_4 | 6.28e-04 | 22 | 24 | 2 | M42574 | |
| Pathway | BIOCARTA_G2_PATHWAY | 7.49e-04 | 24 | 24 | 2 | M8560 | |
| Pathway | REACTOME_PLASMA_LIPOPROTEIN_REMODELING | 8.14e-04 | 25 | 24 | 2 | MM15562 | |
| Pathway | REACTOME_HOMOLOGOUS_DNA_PAIRING_AND_STRAND_EXCHANGE | 8.81e-04 | 26 | 24 | 2 | MM15297 | |
| Pathway | KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_LACTO_AND_NEOLACTO_SERIES | 8.81e-04 | 26 | 24 | 2 | M17377 | |
| Pathway | REACTOME_RESOLUTION_OF_D_LOOP_STRUCTURES_THROUGH_SYNTHESIS_DEPENDENT_STRAND_ANNEALING_SDSA | 9.50e-04 | 27 | 24 | 2 | M27586 | |
| Pathway | REACTOME_TRP_CHANNELS | 1.02e-03 | 28 | 24 | 2 | MM14943 | |
| Pathway | REACTOME_TRP_CHANNELS | 1.02e-03 | 28 | 24 | 2 | M27241 | |
| Pathway | REACTOME_MEIOSIS | 1.07e-03 | 120 | 24 | 3 | M529 | |
| Pathway | REACTOME_PLASMA_LIPOPROTEIN_REMODELING | 1.51e-03 | 34 | 24 | 2 | M27842 | |
| Pathway | REACTOME_RESOLUTION_OF_D_LOOP_STRUCTURES | 1.60e-03 | 35 | 24 | 2 | MM15293 | |
| Pathway | REACTOME_STRIATED_MUSCLE_CONTRACTION | 1.60e-03 | 35 | 24 | 2 | MM15005 | |
| Pathway | REACTOME_STRIATED_MUSCLE_CONTRACTION | 1.69e-03 | 36 | 24 | 2 | M18647 | |
| Pathway | REACTOME_RESOLUTION_OF_D_LOOP_STRUCTURES | 1.78e-03 | 37 | 24 | 2 | M27583 | |
| Pathway | WP_MALE_INFERTILITY | 1.84e-03 | 145 | 24 | 3 | M39856 | |
| Pathway | PID_FOXM1_PATHWAY | 2.08e-03 | 40 | 24 | 2 | M176 | |
| Pathway | WP_MYOMETRIAL_RELAXATION_AND_CONTRACTION_PATHWAYS | 2.27e-03 | 156 | 24 | 3 | M39475 | |
| Pathway | REACTOME_REPRODUCTION | 2.35e-03 | 158 | 24 | 3 | M26956 | |
| Pathway | REACTOME_HOMOLOGOUS_DNA_PAIRING_AND_STRAND_EXCHANGE | 2.40e-03 | 43 | 24 | 2 | M27588 | |
| Pathway | REACTOME_NETRIN_1_SIGNALING | 2.52e-03 | 44 | 24 | 2 | M875 | |
| Pathway | REACTOME_MUSCLE_CONTRACTION | 2.66e-03 | 165 | 24 | 3 | MM15026 | |
| Pathway | PID_DELTA_NP63_PATHWAY | 2.87e-03 | 47 | 24 | 2 | M236 | |
| Pathway | PID_FANCONI_PATHWAY | 2.87e-03 | 47 | 24 | 2 | M1 | |
| Pathway | PID_HES_HEY_PATHWAY | 2.99e-03 | 48 | 24 | 2 | M288 | |
| Pathway | REACTOME_DISEASES_OF_DNA_REPAIR | 3.37e-03 | 51 | 24 | 2 | M29854 | |
| Pathway | WP_CCL18_SIGNALING | 3.50e-03 | 52 | 24 | 2 | M42542 | |
| Pathway | REACTOME_GLYCOSPHINGOLIPID_METABOLISM | 3.63e-03 | 53 | 24 | 2 | MM14647 | |
| Pathway | REACTOME_DNA_DAMAGE_TELOMERE_STRESS_INDUCED_SENESCENCE | 3.77e-03 | 54 | 24 | 2 | MM14904 | |
| Pathway | WP_DNA_IRDOUBLE_STRAND_BREAKS_AND_CELLULAR_RESPONSE_VIA_ATM | 3.90e-03 | 55 | 24 | 2 | M39598 | |
| Pathway | REACTOME_GLYCOSPHINGOLIPID_METABOLISM | 4.33e-03 | 58 | 24 | 2 | M576 | |
| Pathway | PID_P53_REGULATION_PATHWAY | 4.48e-03 | 59 | 24 | 2 | M261 | |
| Pathway | REACTOME_HDR_THROUGH_HOMOLOGOUS_RECOMBINATION_HRR | 4.48e-03 | 59 | 24 | 2 | MM15283 | |
| Pubmed | Reexamination of chromosomal loci of human muscle actin genes by fluorescence in situ hybridization. | 1.20e-09 | 3 | 38 | 3 | 7780165 | |
| Pubmed | Virus assembly and plasma membrane domains: which came first? | 2.40e-08 | 6 | 38 | 3 | 22989508 | |
| Pubmed | HIV-1 protease cleaves actin during acute infection of human T-lymphocytes. | 2.40e-08 | 6 | 38 | 3 | 1540415 | |
| Pubmed | HIV type 1 Gag and nucleocapsid proteins: cytoskeletal localization and effects on cell motility. | 2.40e-08 | 6 | 38 | 3 | 11709093 | |
| Pubmed | Actin associates with the nucleocapsid domain of the human immunodeficiency virus Gag polyprotein. | 2.40e-08 | 6 | 38 | 3 | 9971772 | |
| Pubmed | 2.40e-08 | 6 | 38 | 3 | 10049817 | ||
| Pubmed | 2.40e-08 | 6 | 38 | 3 | 12009869 | ||
| Pubmed | HIV-1 Tat protein variants: critical role for the cysteine region in synaptodendritic injury. | 2.40e-08 | 6 | 38 | 3 | 23811015 | |
| Pubmed | Retroviral assembly and budding occur through an actin-driven mechanism. | 2.40e-08 | 6 | 38 | 3 | 19883584 | |
| Pubmed | Dynamic imaging of cell-free and cell-associated viral capture in mature dendritic cells. | 2.40e-08 | 6 | 38 | 3 | 21917091 | |
| Pubmed | HIV-1 Gag protein associates with F-actin present in microfilaments. | 2.40e-08 | 6 | 38 | 3 | 8661406 | |
| Pubmed | 2.40e-08 | 6 | 38 | 3 | 23017337 | ||
| Pubmed | Interaction of the human immunodeficiency virus type 1 nucleocapsid with actin. | 2.40e-08 | 6 | 38 | 3 | 10074138 | |
| Pubmed | Synaptodendritic recovery following HIV Tat exposure: neurorestoration by phytoestrogens. | 2.40e-08 | 6 | 38 | 3 | 23875777 | |
| Pubmed | 2.40e-08 | 6 | 38 | 3 | 9841925 | ||
| Pubmed | HIV-1 replication from after cell entry to the nuclear periphery. | 4.20e-08 | 7 | 38 | 3 | 17504171 | |
| Pubmed | 4.20e-08 | 7 | 38 | 3 | 22535526 | ||
| Pubmed | 4.20e-08 | 7 | 38 | 3 | 22465675 | ||
| Pubmed | Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. | 4.20e-08 | 7 | 38 | 3 | 9384381 | |
| Pubmed | 4.20e-08 | 7 | 38 | 3 | 30289203 | ||
| Pubmed | Selective targeting of ITK blocks multiple steps of HIV replication. | 4.20e-08 | 7 | 38 | 3 | 18443296 | |
| Pubmed | The trinity of the cortical actin in the initiation of HIV-1 infection. | 4.20e-08 | 7 | 38 | 3 | 22640593 | |
| Pubmed | 6.71e-08 | 8 | 38 | 3 | 14694110 | ||
| Pubmed | 6.71e-08 | 8 | 38 | 3 | 20147394 | ||
| Pubmed | 6.71e-08 | 8 | 38 | 3 | 23260110 | ||
| Pubmed | 6.71e-08 | 8 | 38 | 3 | 20096780 | ||
| Pubmed | Modulation of cardiac growth and development by HOP, an unusual homeodomain protein. | 1.01e-07 | 9 | 38 | 3 | 12297046 | |
| Pubmed | Cytoskeletal proteins inside human immunodeficiency virus type 1 virions. | 1.01e-07 | 9 | 38 | 3 | 8892894 | |
| Pubmed | Functional interaction between the cytoplasmic leucine-zipper domain of HIV-1 gp41 and p115-RhoGEF. | 1.01e-07 | 9 | 38 | 3 | 10556093 | |
| Pubmed | 1.01e-07 | 9 | 38 | 3 | 18775311 | ||
| Pubmed | Altered versican cleavage in ADAMTS5 deficient mice; a novel etiology of myxomatous valve disease. | 1.44e-07 | 10 | 38 | 3 | 21749862 | |
| Pubmed | Non-viral cellular substrates for human immunodeficiency virus type 1 protease. | 1.44e-07 | 10 | 38 | 3 | 1991513 | |
| Pubmed | 1.44e-07 | 10 | 38 | 3 | 23575248 | ||
| Pubmed | 1.44e-07 | 10 | 38 | 3 | 1907279 | ||
| Pubmed | 1.97e-07 | 11 | 38 | 3 | 30962377 | ||
| Pubmed | N-terminal Slit2 inhibits HIV-1 replication by regulating the actin cytoskeleton. | 1.97e-07 | 11 | 38 | 3 | 23294842 | |
| Pubmed | Quantitative proteomic analysis of lentiviral vectors using 2-DE. | 1.97e-07 | 11 | 38 | 3 | 19639585 | |
| Pubmed | 1.97e-07 | 11 | 38 | 3 | 22207710 | ||
| Pubmed | 2.63e-07 | 12 | 38 | 3 | 23071112 | ||
| Pubmed | SEMA6D regulates perinatal cardiomyocyte proliferation and maturation in mice. | 2.63e-07 | 12 | 38 | 3 | 31042497 | |
| Pubmed | Loss of both GATA4 and GATA6 blocks cardiac myocyte differentiation and results in acardia in mice. | 3.42e-07 | 13 | 38 | 3 | 18400219 | |
| Pubmed | 4.34e-07 | 14 | 38 | 3 | 21923909 | ||
| Pubmed | 4.34e-07 | 14 | 38 | 3 | 17411366 | ||
| Pubmed | 5.43e-07 | 15 | 38 | 3 | 24598388 | ||
| Pubmed | Extraocular muscle morphogenesis and gene expression are regulated by Pitx2 gene dose. | 6.67e-07 | 16 | 38 | 3 | 16638982 | |
| Pubmed | Serum response factor is essential for mesoderm formation during mouse embryogenesis. | 6.67e-07 | 16 | 38 | 3 | 9799237 | |
| Pubmed | 8.10e-07 | 17 | 38 | 3 | 17360745 | ||
| Pubmed | 8.10e-07 | 17 | 38 | 3 | 8997639 | ||
| Pubmed | 9.71e-07 | 18 | 38 | 3 | 24840128 | ||
| Pubmed | 9.71e-07 | 18 | 38 | 3 | 15929941 | ||
| Pubmed | 1.15e-06 | 19 | 38 | 3 | 30700554 | ||
| Pubmed | Heart-specific ablation of Prkar1a causes failure of heart development and myxomagenesis. | 1.15e-06 | 19 | 38 | 3 | 18316483 | |
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 34899056 | ||
| Pubmed | Corticolimbic expression of TRPC4 and TRPC5 channels in the rodent brain. | 1.16e-06 | 2 | 38 | 2 | 17593972 | |
| Pubmed | Rescue of skeletal muscle alpha-actin-null mice by cardiac (fetal) alpha-actin. | 1.16e-06 | 2 | 38 | 2 | 19468071 | |
| Pubmed | Two prevalent h alleles in para-Bombay haplotypes among 250,000 Taiwanese. | 1.16e-06 | 2 | 38 | 2 | 15487706 | |
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 20706863 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 34487549 | ||
| Pubmed | alpha-Actin proteins and gene transcripts are colocalized in embryonic mouse muscle. | 1.16e-06 | 2 | 38 | 2 | 1893870 | |
| Pubmed | Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer. | 1.16e-06 | 2 | 38 | 2 | 27692705 | |
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 26317356 | ||
| Pubmed | Increased susceptibility of secretor factor gene Fut2-null mice to experimental vaginal candidiasis. | 1.16e-06 | 2 | 38 | 2 | 15213174 | |
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 16884711 | ||
| Pubmed | A novel capacitative calcium entry channel expressed in excitable cells. | 1.16e-06 | 2 | 38 | 2 | 9687496 | |
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 27834485 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 19527073 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 3023046 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 9299444 | ||
| Pubmed | Point mutations and deletion responsible for the Bombay H null and the Reunion H weak blood groups. | 1.16e-06 | 2 | 38 | 2 | 9745152 | |
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 24527852 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 14967068 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 34533610 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 25761312 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 11713270 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 17922418 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 22053055 | ||
| Pubmed | Muscle specific expression of Cre recombinase under two actin promoters in transgenic mice. | 1.16e-06 | 2 | 38 | 2 | 10686609 | |
| Pubmed | Widespread gene conversion of alpha-2-fucosyltransferase genes in mammals. | 1.16e-06 | 2 | 38 | 2 | 19533213 | |
| Pubmed | [Analysis on FUT1 and FUT2 gene of 10 para-Bombay individuals in China]. | 1.16e-06 | 2 | 38 | 2 | 15476160 | |
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 3075543 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 22457348 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 21172308 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 23677990 | ||
| Pubmed | The human chromosome 19 linkage group FUT1 (H), FUT2 (SE), LE, LU, PEPD, C3, APOC2, D19S7 and D19S9. | 1.16e-06 | 2 | 38 | 2 | 1763885 | |
| Pubmed | Ataxia telangiectasia mutated (ATM) interacts with p400 ATPase for an efficient DNA damage response. | 1.16e-06 | 2 | 38 | 2 | 27814680 | |
| Pubmed | Involvement of TRPC4 and 5 Channels in Persistent Firing in Hippocampal CA1 Pyramidal Cells. | 1.16e-06 | 2 | 38 | 2 | 32033274 | |
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 37126020 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 17624425 | ||
| Pubmed | 1.16e-06 | 2 | 38 | 2 | 2731651 | ||
| Pubmed | A fetal skeletal muscle actin mRNA in the mouse and its identity with cardiac actin mRNA. | 1.16e-06 | 2 | 38 | 2 | 6897014 | |
| Pubmed | TRPC4/TRPC5 channels mediate adverse reaction to the cancer cell cytotoxic agent (-)-Englerin A. | 1.16e-06 | 2 | 38 | 2 | 30038709 | |
| Pubmed | 1.58e-06 | 21 | 38 | 3 | 20230754 | ||
| Pubmed | Myocardial Mycn is essential for mouse ventricular wall morphogenesis. | 1.58e-06 | 21 | 38 | 3 | 23063798 | |
| Pubmed | Modifications in the human T cell proteome induced by intracellular HIV-1 Tat protein expression. | 1.83e-06 | 22 | 38 | 3 | 16526095 | |
| Pubmed | Essential and supporting host cell factors for HIV-1 budding. | 2.10e-06 | 23 | 38 | 3 | 22004035 | |
| Pubmed | 3.07e-06 | 26 | 38 | 3 | 24742657 | ||
| Pubmed | 3.48e-06 | 3 | 38 | 2 | 11179967 | ||
| Pubmed | 3.48e-06 | 3 | 38 | 2 | 28790178 | ||
| Pubmed | 3.48e-06 | 3 | 38 | 2 | 34517749 | ||
| Pubmed | BRCA2 is required for neurogenesis and suppression of medulloblastoma. | 3.48e-06 | 3 | 38 | 2 | 17476307 | |
| Interaction | PFN3 interactions | 6.78e-07 | 10 | 37 | 3 | int:PFN3 | |
| Interaction | ACTG2 interactions | 1.92e-06 | 49 | 37 | 4 | int:ACTG2 | |
| Interaction | POTEJ interactions | 2.44e-06 | 52 | 37 | 4 | int:POTEJ | |
| Interaction | CAP2 interactions | 6.39e-06 | 66 | 37 | 4 | int:CAP2 | |
| Interaction | NEXN interactions | 2.29e-05 | 91 | 37 | 4 | int:NEXN | |
| Interaction | ABRA interactions | 3.90e-05 | 36 | 37 | 3 | int:ABRA | |
| Interaction | POTEI interactions | 4.03e-05 | 105 | 37 | 4 | int:POTEI | |
| Interaction | ERRFI1 interactions | 4.33e-05 | 107 | 37 | 4 | int:ERRFI1 | |
| Interaction | GANAB interactions | 5.13e-05 | 368 | 37 | 6 | int:GANAB | |
| Interaction | ACTA1 interactions | 5.36e-05 | 371 | 37 | 6 | int:ACTA1 | |
| Interaction | DNASE1 interactions | 6.85e-05 | 7 | 37 | 2 | int:DNASE1 | |
| Interaction | POTEE interactions | 1.04e-04 | 134 | 37 | 4 | int:POTEE | |
| Interaction | HOXB3 interactions | 1.17e-04 | 9 | 37 | 2 | int:HOXB3 | |
| Interaction | PLEC interactions | 1.21e-04 | 430 | 37 | 6 | int:PLEC | |
| Interaction | MSH6 interactions | 1.30e-04 | 271 | 37 | 5 | int:MSH6 | |
| Interaction | ANGPTL8 interactions | 1.46e-04 | 10 | 37 | 2 | int:ANGPTL8 | |
| Interaction | SLCO1B3 interactions | 1.46e-04 | 10 | 37 | 2 | int:SLCO1B3 | |
| Interaction | UGT1A7 interactions | 1.56e-04 | 57 | 37 | 3 | int:UGT1A7 | |
| Interaction | SCIN interactions | 1.64e-04 | 58 | 37 | 3 | int:SCIN | |
| Interaction | WASH8P interactions | 1.79e-04 | 11 | 37 | 2 | int:WASH8P | |
| Interaction | ACTBL2 interactions | 1.96e-04 | 296 | 37 | 5 | int:ACTBL2 | |
| Interaction | GC interactions | 2.00e-04 | 62 | 37 | 3 | int:GC | |
| Interaction | SELENOP interactions | 2.14e-04 | 12 | 37 | 2 | int:SELENOP | |
| Interaction | PPP1R1A interactions | 2.53e-04 | 13 | 37 | 2 | int:PPP1R1A | |
| Interaction | PCYT1B interactions | 2.53e-04 | 13 | 37 | 2 | int:PCYT1B | |
| Interaction | TPSAB1 interactions | 2.94e-04 | 14 | 37 | 2 | int:TPSAB1 | |
| Interaction | PDIA6 interactions | 3.10e-04 | 327 | 37 | 5 | int:PDIA6 | |
| Interaction | FBXO40 interactions | 3.39e-04 | 15 | 37 | 2 | int:FBXO40 | |
| Interaction | NAA80 interactions | 3.39e-04 | 15 | 37 | 2 | int:NAA80 | |
| Interaction | TERF2 interactions | 3.71e-04 | 340 | 37 | 5 | int:TERF2 | |
| Interaction | HSD17B4 interactions | 3.96e-04 | 190 | 37 | 4 | int:HSD17B4 | |
| Interaction | DMAP1 interactions | 4.04e-04 | 191 | 37 | 4 | int:DMAP1 | |
| Interaction | FEN1 interactions | 4.21e-04 | 193 | 37 | 4 | int:FEN1 | |
| Interaction | TMSB4X interactions | 4.25e-04 | 80 | 37 | 3 | int:TMSB4X | |
| Interaction | REG3A interactions | 4.38e-04 | 17 | 37 | 2 | int:REG3A | |
| Interaction | NHEJ1 interactions | 4.38e-04 | 17 | 37 | 2 | int:NHEJ1 | |
| Interaction | STAT2 interactions | 4.40e-04 | 81 | 37 | 3 | int:STAT2 | |
| Interaction | ACTA2 interactions | 4.52e-04 | 355 | 37 | 5 | int:ACTA2 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr1q42 | 1.04e-03 | 240 | 38 | 3 | chr1q42 | |
| Cytoband | 19q13.3 | 2.12e-03 | 82 | 38 | 2 | 19q13.3 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr13q13 | 2.12e-03 | 82 | 38 | 2 | chr13q13 | |
| GeneFamily | Actins | 5.26e-08 | 6 | 26 | 3 | 929 | |
| GeneFamily | Fucosyltransferases|Blood group antigens | 1.54e-04 | 13 | 26 | 2 | 434 | |
| GeneFamily | Transient receptor potential cation channels | 7.35e-04 | 28 | 26 | 2 | 249 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_P1_bladder_J_emap-30374_k-means-cluster#4_top-relative-expression-ranked_100 | 1.34e-05 | 26 | 38 | 3 | gudmap_developingLowerUrinaryTract_P1_bladder_J_100_k4 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_P1_bladder_B_emap-30374_k-means-cluster#3_top-relative-expression-ranked_100 | 1.68e-05 | 28 | 38 | 3 | gudmap_developingLowerUrinaryTract_P1_bladder_B_100_k3 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30892_k-means-cluster#4_top-relative-expression-ranked_500 | 8.65e-05 | 48 | 38 | 3 | gudmap_developingLowerUrinaryTract_e14.5_ urethra_500_k4 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_P1_bladder_B_emap-30374_k-means-cluster#2_top-relative-expression-ranked_200 | 9.78e-05 | 50 | 38 | 3 | gudmap_developingLowerUrinaryTract_P1_bladder_B_200_k2 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e15.5_ureteral tissue_emap-8234_k-means-cluster#3_top-relative-expression-ranked_100 | 1.11e-04 | 9 | 38 | 2 | gudmap_developingLowerUrinaryTract_e15.5_ureteral tissue_100_k3 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_2(PVALB)-WFDC2--L2-4|Neuronal / cells hierarchy compared to all cells using T-Statistic | 7.36e-07 | 200 | 38 | 5 | c65e6336725856c4b5f6aeba1cf86a23ec815d34 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_2(PVALB)-WFDC2-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 7.36e-07 | 200 | 38 | 5 | 117a25b3b9cdbc2e198381350a8362bee25e82e7 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_2(PVALB)-WFDC2|Neuronal / cells hierarchy compared to all cells using T-Statistic | 7.36e-07 | 200 | 38 | 5 | d459e51507bf26865e6e7e04411379ec82a3edf8 | |
| ToppCell | (08)_PNEC-(2)_48hpi|(08)_PNEC / shred by cell type and Timepoint | 6.46e-06 | 142 | 38 | 4 | e95d34170f5053678e0dd9793e68d93c03b05822 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Peritubular_Capilary_Endothelial_Cell__prolif|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.01e-05 | 159 | 38 | 4 | c960df9e4fa980401941866b5081facac4590b4d | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Immune-Lymphocytic_B-Plasma_Cell-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.09e-05 | 162 | 38 | 4 | 8ed9149ff53b285591354057055d072b203a47c8 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Immune-Lymphocytic_B-Plasma_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.09e-05 | 162 | 38 | 4 | 7a05b05a33e1309fb5c0a8171db105ae68491815 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5_PVALB_CNTNAP3P2|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.57e-05 | 178 | 38 | 4 | 6ad46b0720298bcb927fd53468bb4ea0c199ad35 | |
| ToppCell | COVID-19-kidney-vSMC/Pericyte|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.61e-05 | 179 | 38 | 4 | 111b1084f73306bdeffaaf240e7dbb4f5bf33de1 | |
| ToppCell | Children_(3_yrs)-Mesenchymal-pericyte_cell-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.68e-05 | 181 | 38 | 4 | 451b87ac95154bb80018b8dd245b4a6389d81411 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.75e-05 | 183 | 38 | 4 | 04d3cc76038b8192c915f1c08c3e26f2ad3b3779 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.79e-05 | 184 | 38 | 4 | 2ba98708dfd7f1b2a661578a334684094ff453ad | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L3-4_PVALB_HOMER3|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.87e-05 | 186 | 38 | 4 | 948815663c212c4311329d503b5991cbbbff9808 | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-pericyte_cell-D062|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 1.95e-05 | 188 | 38 | 4 | ccddc08121caff958a2b6f9e278a018858af6b4d | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.95e-05 | 188 | 38 | 4 | 8de5a07301f9b5984680c873e5a92395b5ed3dd3 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.99e-05 | 189 | 38 | 4 | 78cf414b98bcb19deb934409acddaad1cd51b67f | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.03e-05 | 190 | 38 | 4 | 3f22c118d552345f731d4d49f0bcb5765d93de3b | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.03e-05 | 190 | 38 | 4 | 305fbef734c350cfbf786ca7ff6e07093aab56ea | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.03e-05 | 190 | 38 | 4 | 39ab890104b4264c68a968f920f4ccd84f0bc681 | |
| ToppCell | COVID-19-Heart-EC_+_Pericyte|Heart / Disease (COVID-19 only), tissue and cell type | 2.03e-05 | 190 | 38 | 4 | a21653bfb7bafbc273f94fa7c13bfb48cf8fd562 | |
| ToppCell | nucseq-Mesenchymal-Myocytic-Myocytic_1-Pericyte|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.03e-05 | 190 | 38 | 4 | 4eb92aef1ee868f4537483d19014d947b7684612 | |
| ToppCell | nucseq-Mesenchymal-Myocytic-Myocytic_1|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.03e-05 | 190 | 38 | 4 | 7be4341e2909101d756f14031c21e705eb45e69a | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.03e-05 | 190 | 38 | 4 | 8c9c230a509afaeee50644153974a5642b01a2b8 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Myocytic_interstitial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.08e-05 | 191 | 38 | 4 | 04c4d454b57e29a8d1dcdeb4678ce71bdc29b77b | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5_PVALB_CNTNAP3P2|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.12e-05 | 192 | 38 | 4 | 0003d7ef9a8e521e70ac33c63aad843d9b6215c2 | |
| ToppCell | 368C-Fibroblasts-Fibroblast-K_(Pericytes)-|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 2.16e-05 | 193 | 38 | 4 | 5ec917931b438dd0e7fb03eb6af459d3ef6b84ba | |
| ToppCell | 368C-Fibroblasts-Fibroblast-K_(Pericytes)|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 2.16e-05 | 193 | 38 | 4 | 5260ac95a15cc43a19909badad0c7e3854da920d | |
| ToppCell | 10x_3'_v3-thymus_(10x_3'_v3)-lymphocytic-T_lymphocytic-CD8-positive,_alpha-beta_T_cell|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 2.16e-05 | 193 | 38 | 4 | a594f89a18273797506287d9e22f72abe53e4920 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.16e-05 | 193 | 38 | 4 | c4b22b62f3cc7bf0ec0eba76e1504c236290bbc9 | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_myocytic-mes_proliferating_SM_(20)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 2.16e-05 | 193 | 38 | 4 | 516ea2c12bdc7a5dc676159d627e36f6abe13ef0 | |
| ToppCell | severe-low-quality_cells|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.16e-05 | 193 | 38 | 4 | 9337bc93e3904c7fc7c93c328518bcd6453b1e8c | |
| ToppCell | nucseq-Epithelial-Epithelial_Alveolar|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.21e-05 | 194 | 38 | 4 | 53f3e49e91b1096f3226010e2de767efb490dfe4 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.21e-05 | 194 | 38 | 4 | a52c5906fce43c2f72cf7e463a3d15cde06431f6 | |
| ToppCell | nucseq-Epithelial|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.25e-05 | 195 | 38 | 4 | 9406866f99555198a9be311fbd65751b70f35446 | |
| ToppCell | CTRL|World / Disease state, Lineage and Cell class | 2.25e-05 | 195 | 38 | 4 | cad77cdc6e0aa0875eff5ecd3805a6cf056d729d | |
| ToppCell | COVID-19_Severe-CD8+_Tem|COVID-19_Severe / disease group, cell group and cell class | 2.30e-05 | 196 | 38 | 4 | 1bc1ec3351319c5d2daa0808cf161a7327e1758e | |
| ToppCell | (5)_Fibroblasts-(5)_Fibroblast-K_(Pericytes)|(5)_Fibroblasts / Lung cell shreds - cell class (v4) and cell subclass (v4) | 2.30e-05 | 196 | 38 | 4 | 541b1fcf509e362f6f48720046cb5378aaf7c591 | |
| ToppCell | Parenchymal-NucSeq-Stromal-Pericyte|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.34e-05 | 197 | 38 | 4 | 41dd312f46a2b983c8d864adeb6970c0ca4a8048 | |
| ToppCell | Parenchymal-NucSeq-Stromal-Pericyte-Muscle_pericyte_pulmonary|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.34e-05 | 197 | 38 | 4 | f66945f9007d59d4208849c7fd727f8519713fbc | |
| ToppCell | severe-low-quality_cells|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.34e-05 | 197 | 38 | 4 | 57ebd552f10d6278623b52a3d484d4b91ae1d028 | |
| ToppCell | mild-low-quality_cells|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 2.34e-05 | 197 | 38 | 4 | e4331969bd911d1ebb5453f40a7057297b5389b4 | |
| ToppCell | Tracheal-10x3prime_v2-Stromal-Myofibroblastic|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 2.44e-05 | 199 | 38 | 4 | 534dcfe8b65ad92bb8d749d1c7036ad4807e09cd | |
| ToppCell | Bronchial-NucSeq-Stromal-Pericyte-Muscle_pericyte_pulmonary|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.44e-05 | 199 | 38 | 4 | 929f809579368201331d9099d8904b6e3c41797b | |
| ToppCell | Bronchial-NucSeq-Stromal-Pericyte|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.44e-05 | 199 | 38 | 4 | 854628ce91068093c14bd4d45ba38c41469f3549 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_2(PVALB)-SULF1--L4-6|Neuronal / cells hierarchy compared to all cells using T-Statistic | 2.48e-05 | 200 | 38 | 4 | 4a426ef88376d8bb2b9dc50aa06e7b9fc50ecc9c | |
| ToppCell | Neuronal-Inhibitory-iB-iB_2(PVALB)|Neuronal / cells hierarchy compared to all cells using T-Statistic | 2.48e-05 | 200 | 38 | 4 | 1276bfa911fddada4235e12e3081baa53164574b | |
| ToppCell | Parenchymal-10x3prime_v2-Stromal-Pericyte|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 2.48e-05 | 200 | 38 | 4 | d70bad979299615fcba707ba21296020918705e6 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_2(PVALB)-SULF1|Neuronal / cells hierarchy compared to all cells using T-Statistic | 2.48e-05 | 200 | 38 | 4 | fbeee1c16ac0a7fe28d90491c8b079f21ce80bdc | |
| ToppCell | Neuronal-Inhibitory-iB-iB_2(PVALB)-SULF1-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 2.48e-05 | 200 | 38 | 4 | c6eda342ea0cb37d71d89dbb8d11e819e0745172 | |
| ToppCell | Parenchymal-10x3prime_v2-Stromal-Pericyte-Muscle_pericyte_pulmonary|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 2.48e-05 | 200 | 38 | 4 | 38c21ec379005f688df33aea65237a063c476c2e | |
| ToppCell | LPS-antiTNF-Myeloid-Dendritic_cells-pDC|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.81e-04 | 129 | 38 | 3 | 454bae525f6db3d0dd6347d2a2c3ea9dda9cd212 | |
| ToppCell | LPS_only-Myeloid-Dendritic_cells-pDC|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.06e-04 | 135 | 38 | 3 | 0afe232aa1a1e6c37a5b3183b67d7fa07e0ea791 | |
| ToppCell | 10x3'2.3-week_12-13-Myeloid_DC-DC-DC_precursor|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 2.20e-04 | 138 | 38 | 3 | 096c0c8ed396a27d29cca94e2e15099b64129c57 | |
| ToppCell | COVID-19-kidney-Mito-rich_EC|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.55e-04 | 145 | 38 | 3 | afed661aef990edb8e7012ab67ace56443520c9f | |
| ToppCell | LPS-IL1RA+antiTNF-Myeloid-Dendritic_cells-pDC|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.92e-04 | 152 | 38 | 3 | 0c6dd41142e4ca1e54ca41e05e42ed29fbf0e570 | |
| ToppCell | primary_visual_cortex-Neuronal-GABAergic_neuron-Lamp5-Lamp5_Ntn1_Npy2r|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 2.92e-04 | 152 | 38 | 3 | 8ff5a178a8f3550d89a003c0858820aab3773386 | |
| ToppCell | Influenza_Severe-Treg|Influenza_Severe / Disease group and Cell class | 3.04e-04 | 154 | 38 | 3 | 77845bcb243aa1b1f1ca00f9ef2ae1b4d1bd3696 | |
| ToppCell | LPS-IL1RA-Myeloid-Dendritic_cells-pDC|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.40e-04 | 160 | 38 | 3 | dee756a2dc9725520d439e7273c489c2284015d8 | |
| ToppCell | Influenza_Severe-gd_T|World / Disease group and Cell class | 3.46e-04 | 161 | 38 | 3 | b3cdaed4d58d57e3c5dbc904a09388f3bf949407 | |
| ToppCell | facs-Thymus-Epithelium-3m-Epithelial-TECs|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.52e-04 | 162 | 38 | 3 | 25323785dd33337bcefd05958a4a1a208a9ceb04 | |
| ToppCell | facs-Thymus-Epithelium-3m-Epithelial-epithelial_cell_of_thymus|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.52e-04 | 162 | 38 | 3 | 3dc39db0d5f6f3d7bcc312a6bce7aaeb914138d1 | |
| ToppCell | facs-Thymus-Epithelium-3m-Epithelial|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.52e-04 | 162 | 38 | 3 | 0a7138266054ea5954649c8b61ef93905d56b068 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_T-CytoT_GZMK+-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 3.52e-04 | 162 | 38 | 3 | 19395bdb282b4a2d88cd33191af12c24a88c3d16 | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-vascular_smooth_muscle_cell-D062|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 3.59e-04 | 163 | 38 | 3 | 51dee6c21cbeca4e17d1cc386e203f0c403089e8 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell-mesangial_typical-aged|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 3.65e-04 | 164 | 38 | 3 | f6a961fa2002da7d9679f32af99e1314c0593ef9 | |
| ToppCell | normal-na-Lymphocytic_NK-NK_bright-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 3.65e-04 | 164 | 38 | 3 | b5a91f2cbfad9a2bc38aea576085a37865df955d | |
| ToppCell | 15-Airway-Mesenchymal-Airway_Smooth_Muscle|Airway / Age, Tissue, Lineage and Cell class | 3.72e-04 | 165 | 38 | 3 | 531804467601e1ee1f771cffa21501f6d464ae10 | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Mesenchymal--glomerular_mesenchymal_cell-Renin-positive_Juxtaglomerular_Granular_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 3.72e-04 | 165 | 38 | 3 | 9de841c1c95967c562720feba930246debc626fd | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 3.72e-04 | 165 | 38 | 3 | a612a7d3a5415ecacc3df8fbff0ce498f982aad0 | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Mesenchymal--glomerular_mesenchymal_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 3.72e-04 | 165 | 38 | 3 | cdc94a640ec01c6892521bcd6f0ee0a66ff23866 | |
| ToppCell | PND01-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-ASMC|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.78e-04 | 166 | 38 | 3 | 9a341dc7b756252caeaac1e934384911c880a634 | |
| ToppCell | PND01-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-ASMC-ASMC_mature|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.78e-04 | 166 | 38 | 3 | 390cf5e56b72fcaf3b8520930bd35a3e3e173711 | |
| ToppCell | Tuft-tuft-1|World / Class top | 3.92e-04 | 168 | 38 | 3 | 8ddc2ec483ed2c6c0fb2ae521c6861ceb6d32e34 | |
| ToppCell | ICU-NoSEP-Lymphocyte-T_NK-CD4_CTL|ICU-NoSEP / Disease, Lineage and Cell Type | 3.99e-04 | 169 | 38 | 3 | cbda36f32bd78322dcfe303a44413415d08e5ea3 | |
| ToppCell | PND07-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-ASMC|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 4.06e-04 | 170 | 38 | 3 | da4fb1e186e9bec6bba0b25f2a0e68f9e11c6017 | |
| ToppCell | PND07-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-ASMC-ASMC_mature|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 4.06e-04 | 170 | 38 | 3 | cb1ed6bd409ee1cf11be0d5e7cdcffe2ab220d38 | |
| ToppCell | Influenza_Severe-gd_T|Influenza_Severe / Disease group and Cell class | 4.06e-04 | 170 | 38 | 3 | 59009c5a504ea8c6b4f6697299db219fd5edf7d6 | |
| ToppCell | droplet-Lung-21m-Hematologic-lymphocytic-CD8-positive,_alpha-beta_T_cell-CD8-positive,_alpha-beta_T_cell_l48|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.06e-04 | 170 | 38 | 3 | 070d8683d1a5cc7d594ff0453c961a9bf982c2d0 | |
| ToppCell | 3'-Broncho-tracheal-Immune_Myeloid-Dendritic-plasmacytoid_dendritic_cell-Plasmacytoid_DCs-Plasmacytoid_DCs_L.1.5.1.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.13e-04 | 171 | 38 | 3 | 4fd2c7977c512c51507f055fc74b111c0228ed8b | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell-Mesangial_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.20e-04 | 172 | 38 | 3 | 553701349444eb366df3c11f54bb093434f153c6 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-glomerular_mesenchymal_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.20e-04 | 172 | 38 | 3 | 08a3fe536b1b064c5ee7779bc2b1115a5963a26b | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_intercalated_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.27e-04 | 173 | 38 | 3 | 0bc2aacae60c6d3276b0949eb0748b4ac1f56e54 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Degenerative_Vascular_Smooth_Muscle_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.27e-04 | 173 | 38 | 3 | ecbf7167d4bec685e3460d826318544946f5f5c2 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Degenerative_Vascular_Smooth_Muscle_Cell-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.27e-04 | 173 | 38 | 3 | b8dc978c52de64afba21ff6cb32e79f07167448e | |
| ToppCell | COVID-19-kidney-REN+Pericyte|COVID-19 / Disease (COVID-19 only), tissue and cell type | 4.34e-04 | 174 | 38 | 3 | 8393f0b43c767839c1630bcb952d62b42efc788d | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_2-Exc_L3-4_RORB_PRSS12|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.34e-04 | 174 | 38 | 3 | ae363ce736fc8af439f3ad594d7bc2e344db80d4 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5_PVALB_CNTNAP3P2|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.41e-04 | 175 | 38 | 3 | 9d797888edb39fd12fd9cfc698a42b7bed19a5b5 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell_cycling-Cycling_Distal_Convoluted_Tubule_Cell_G2M|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.41e-04 | 175 | 38 | 3 | 876cea684faf42ff3eb4623ad6d7a1fb1276ee02 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L2-4_SST_AHR|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.49e-04 | 176 | 38 | 3 | 322259a35f5c97d73ce7f75835dcdb5c954c91f8 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5-6_PVALB_STON2|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.49e-04 | 176 | 38 | 3 | 682a1dfcc507ec540f5fadf08e872533ea9f0291 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_2-Exc_L3-4_RORB_PRSS12|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.49e-04 | 176 | 38 | 3 | 40993c41c1017b53039a337174fc56632b278609 | |
| ToppCell | E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-ASMC-ASMC_prolif|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 4.49e-04 | 176 | 38 | 3 | 4ed73c73972334f6dc4229920205547823252fa0 | |
| ToppCell | droplet-Marrow-BM-1m-Lymphocytic-late_pro-B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.49e-04 | 176 | 38 | 3 | 2e9073166da4d9fae70ba4f3fdcad35523caf7cd | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-pericyte_cell-Pericytes-Pericytes_L.2.3.1.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.56e-04 | 177 | 38 | 3 | 452ec2df36c6d656a7cdadc55be545ccdb146a29 | |
| ToppCell | Children_(3_yrs)-Mesenchymal-pericyte_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 4.64e-04 | 178 | 38 | 3 | 185b44700f06ec58b3c09c80520502166c965fd6 | |
| ToppCell | facs-Limb_Muscle-Muscle_Diaphragm-18m-Mesenchymal-skeletal_muscle_satellite_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.64e-04 | 178 | 38 | 3 | 56b19f9c9585538fb8a4c3eea2d132b254cf11ef | |
| ToppCell | droplet-Spleen-SPLEEN-1m-Lymphocytic-plasma_cell|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.64e-04 | 178 | 38 | 3 | b902059c3f861108fc64cbdc05e6f44378f5be2c | |
| ToppCell | COVID-19-kidney-REN+Pericyte|kidney / Disease (COVID-19 only), tissue and cell type | 4.72e-04 | 179 | 38 | 3 | 342c1cc4444f51b8dcb30d3adc98285a25669c6e | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_S-high|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.72e-04 | 179 | 38 | 3 | 88d44b04eb5c079531db663ed98ddb20b60feb9a | |
| ToppCell | COVID-19-Heart-VSMC|Heart / Disease (COVID-19 only), tissue and cell type | 4.72e-04 | 179 | 38 | 3 | a69ad6912b5c10bb9f9d800f724c792341e9bab1 | |
| Computational | Muscle genes. | 7.23e-05 | 37 | 24 | 3 | MODULE_512 | |
| Computational | Genes in the cancer module 387. | 1.68e-04 | 49 | 24 | 3 | MODULE_387 | |
| Computational | Genes in the cancer module 329. | 1.90e-04 | 51 | 24 | 3 | MODULE_329 | |
| Drug | AC1L1CWO | 2.98e-07 | 35 | 37 | 4 | CID000002095 | |
| Drug | Nsc687160 | 3.17e-06 | 18 | 37 | 3 | CID005459290 | |
| Drug | tolytoxin | 3.76e-06 | 19 | 37 | 3 | CID006440827 | |
| Drug | m2-19 | 3.76e-06 | 19 | 37 | 3 | CID000079129 | |
| Drug | AC1MNW2N | 5.01e-06 | 70 | 37 | 4 | CID003359490 | |
| Drug | AC1L8NVR | 5.15e-06 | 21 | 37 | 3 | CID000384633 | |
| Drug | NSC312786 | 5.15e-06 | 21 | 37 | 3 | CID000329495 | |
| Drug | CoA group | 5.39e-06 | 433 | 37 | 7 | CID000000317 | |
| Drug | AC1L1DXE | 8.05e-06 | 299 | 37 | 6 | CID000002548 | |
| Drug | AC1L1BDQ | 8.56e-06 | 173 | 37 | 5 | CID000001394 | |
| Drug | plakin | 9.43e-06 | 82 | 37 | 4 | CID000018752 | |
| Drug | CID5288653 | 1.26e-05 | 28 | 37 | 3 | CID005288653 | |
| Drug | AC1L22RD | 1.43e-05 | 91 | 37 | 4 | CID000065183 | |
| Drug | Isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride; Down 200; 16.4uM; MCF7; HT_HG-U133A | 1.49e-05 | 194 | 37 | 5 | 2824_DN | |
| Drug | 2-propylpentanoic acid; Up 200; 50uM; MCF7; HT_HG-U133A_EA | 1.49e-05 | 194 | 37 | 5 | 1060_UP | |
| Drug | Enzyme Activators | 1.54e-05 | 4 | 37 | 2 | ctd:D020536 | |
| Drug | azaspiracid | 1.56e-05 | 30 | 37 | 3 | CID006451158 | |
| Drug | Harmaline hydrochloride dihydrate [6027-98-1]; Down 200; 14uM; PC3; HT_HG-U133A | 1.60e-05 | 197 | 37 | 5 | 6623_DN | |
| Drug | Dizocilpine maleate [77086-22-7]; Down 200; 11.8uM; PC3; HT_HG-U133A | 1.64e-05 | 198 | 37 | 5 | 2069_DN | |
| Drug | Dioxybenzone [131-53-3]; Up 200; 16.4uM; MCF7; HT_HG-U133A | 1.68e-05 | 199 | 37 | 5 | 6478_UP | |
| Drug | Edrophonium chloride [116-38-1]; Down 200; 19.8uM; PC3; HT_HG-U133A | 1.68e-05 | 199 | 37 | 5 | 6655_DN | |
| Drug | AC1L1HS4 | 1.90e-05 | 32 | 37 | 3 | CID000004267 | |
| Drug | sulphoxide | 2.15e-05 | 101 | 37 | 4 | CID000008442 | |
| Drug | N,N'-p-phenylenedimaleimide | 2.28e-05 | 34 | 37 | 3 | CID000076765 | |
| Drug | 1,N6-ethenoadenosine 5'-diphosphate | 2.28e-05 | 34 | 37 | 3 | CID000001312 | |
| Drug | 4-acetylpyridine | 2.56e-05 | 5 | 37 | 2 | CID000014282 | |
| Drug | Irganox 1076 | 2.56e-05 | 5 | 37 | 2 | CID000016386 | |
| Drug | AC1NSKFN | 2.72e-05 | 36 | 37 | 3 | CID005311324 | |
| Drug | epsilon-ATP | 4.04e-05 | 41 | 37 | 3 | CID000162262 | |
| Drug | AC1L8FNU | 5.00e-05 | 44 | 37 | 3 | CID000425429 | |
| Drug | Cefotetanum [inn-latin] | 5.71e-05 | 46 | 37 | 3 | CID000050614 | |
| Drug | pyrene | 5.97e-05 | 131 | 37 | 4 | CID000031423 | |
| Drug | NpCaM | 6.50e-05 | 48 | 37 | 3 | CID000122259 | |
| Drug | AC1Q6LQU | 6.50e-05 | 48 | 37 | 3 | CID000072380 | |
| Drug | NSC60597 | 7.73e-05 | 140 | 37 | 4 | CID000003327 | |
| Drug | NSC106399 | 7.80e-05 | 51 | 37 | 3 | CID000002887 | |
| Drug | Btzo-tdmap | 9.18e-05 | 9 | 37 | 2 | CID000124335 | |
| Drug | selinan | 9.18e-05 | 9 | 37 | 2 | CID000035524 | |
| Drug | ML-9 | 9.33e-05 | 147 | 37 | 4 | CID000004217 | |
| Drug | 3-methylhistidine | 9.78e-05 | 55 | 37 | 3 | CID000064969 | |
| Drug | Carbachol | 1.03e-04 | 56 | 37 | 3 | ctd:D002217 | |
| Drug | Sodium Fluoride | 1.03e-04 | 933 | 37 | 8 | ctd:D012969 | |
| Drug | dihydrocytochalasin B | 1.15e-04 | 58 | 37 | 3 | CID000003064 | |
| Drug | glycine propionyl carnitine | 1.15e-04 | 10 | 37 | 2 | ctd:C000588486 | |
| Drug | thryroxine | 1.22e-04 | 302 | 37 | 5 | CID000000853 | |
| Drug | 2-aminoethoxydiphenyl borate | 1.33e-04 | 61 | 37 | 3 | ctd:C109986 | |
| Drug | oryzalin | 1.47e-04 | 63 | 37 | 3 | CID000029393 | |
| Drug | AC1L2HAX | 1.68e-04 | 12 | 37 | 2 | CID000020942 | |
| Drug | 5-IAF | 1.68e-04 | 66 | 37 | 3 | CID000123822 | |
| Drug | Emodin | 1.75e-04 | 173 | 37 | 4 | ctd:D004642 | |
| Drug | 5'-N-ethylcarboxamidoadenosine | 1.79e-04 | 174 | 37 | 4 | CID000104795 | |
| Drug | AC1L1ERT | 1.92e-04 | 69 | 37 | 3 | CID000002920 | |
| Drug | zinc chromate | 1.98e-04 | 13 | 37 | 2 | ctd:C023616 | |
| Drug | copper cyanide | 1.98e-04 | 13 | 37 | 2 | CID000011009 | |
| Drug | caged ATP | 2.01e-04 | 70 | 37 | 3 | CID000123806 | |
| Drug | L-Carnosine | 2.27e-04 | 73 | 37 | 3 | CID000009369 | |
| Drug | sodium methoxide | 2.31e-04 | 14 | 37 | 2 | CID010942334 | |
| Drug | ATCA | 2.31e-04 | 14 | 37 | 2 | CID000042485 | |
| Drug | Lawesson's reagent | 2.31e-04 | 14 | 37 | 2 | CID000087949 | |
| Drug | Pregnenolone [145-13-1]; Up 200; 12.6uM; MCF7; HT_HG-U133A | 2.35e-04 | 187 | 37 | 4 | 2856_UP | |
| Drug | C3H2N2O3S | 2.37e-04 | 74 | 37 | 3 | CID000448652 | |
| Drug | AC1LD8HW | 2.46e-04 | 75 | 37 | 3 | CID000644061 | |
| Drug | NSC611747 | 2.49e-04 | 352 | 37 | 5 | CID000002534 | |
| Drug | Benzylpenicillin sodium [69-57-8]; Down 200; 11.2uM; MCF7; HT_HG-U133A | 2.55e-04 | 191 | 37 | 4 | 6839_DN | |
| Drug | prochlorperazine dimaleate salt; Down 200; 10uM; HL60; HT_HG-U133A | 2.66e-04 | 193 | 37 | 4 | 2675_DN | |
| Drug | SIRIUS | 2.66e-04 | 77 | 37 | 3 | CID000091750 | |
| Drug | 1-oleoyl-2-acetylglycerol | 2.66e-04 | 15 | 37 | 2 | ctd:C038237 | |
| Drug | Azaguanine-8 [134-58-7]; Down 200; 26.2uM; MCF7; HT_HG-U133A | 2.71e-04 | 194 | 37 | 4 | 1670_DN | |
| Drug | Althiazide [5588-16-9]; Up 200; 10.4uM; HL60; HT_HG-U133A | 2.71e-04 | 194 | 37 | 4 | 2527_UP | |
| Drug | Buflomedil hydrochloride [35543-24-9]; Down 200; 11.6uM; MCF7; HT_HG-U133A | 2.71e-04 | 194 | 37 | 4 | 3274_DN | |
| Drug | Isoconazole [27523-40-6]; Down 200; 9.6uM; PC3; HT_HG-U133A | 2.82e-04 | 196 | 37 | 4 | 2056_DN | |
| Drug | Trapidil [15421-84-8]; Down 200; 19.4uM; HL60; HT_HG-U133A | 2.82e-04 | 196 | 37 | 4 | 3136_DN | |
| Drug | Colistin sulfate [1264-72-8]; Up 200; 3uM; MCF7; HT_HG-U133A | 2.82e-04 | 196 | 37 | 4 | 2851_UP | |
| Drug | AC1L9EF8 | 2.87e-04 | 79 | 37 | 3 | CID000443315 | |
| Drug | Cefotaxime sodium salt [64485-93-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A | 2.87e-04 | 197 | 37 | 4 | 7186_DN | |
| Drug | THIP Hydrochloride; Down 200; 22.6uM; HL60; HT_HG-U133A | 2.87e-04 | 197 | 37 | 4 | 3132_DN | |
| Drug | Trimipramine maleate salt [521-78-8]; Down 200; 9.8uM; HL60; HT_HG-U133A | 2.87e-04 | 197 | 37 | 4 | 3004_DN | |
| Drug | Mepenzolate bromide [76-90-4]; Down 200; 9.6uM; MCF7; HT_HG-U133A | 2.87e-04 | 197 | 37 | 4 | 3829_DN | |
| Drug | Rapamycin; Up 200; 0.1uM; HL60; HT_HG-U133A | 2.87e-04 | 197 | 37 | 4 | 6180_UP | |
| Drug | kinin 9 | 2.87e-04 | 363 | 37 | 5 | CID000006026 | |
| Drug | Cyclopenthiazide [742-20-1]; Up 200; 10.6uM; HL60; HT_HG-U133A | 2.93e-04 | 198 | 37 | 4 | 2905_UP | |
| Drug | Harmol hydrochloride monohydrate [40580-83-4]; Up 200; 15.8uM; PC3; HT_HG-U133A | 2.93e-04 | 198 | 37 | 4 | 7320_UP | |
| Drug | Folinic acid calcium salt [6035-45-6]; Down 200; 7.8uM; HL60; HT_HG-U133A | 2.93e-04 | 198 | 37 | 4 | 2579_DN | |
| Drug | Nitrofurantoin [67-20-9]; Down 200; 16.8uM; MCF7; HT_HG-U133A | 2.93e-04 | 198 | 37 | 4 | 2303_DN | |
| Drug | Halofantrine hydrochloride [36167-63-2]; Down 200; 7.4uM; HL60; HT_HG-U133A | 2.93e-04 | 198 | 37 | 4 | 3130_DN | |
| Drug | LY-171,883; Up 200; 1uM; MCF7; HG-U133A | 2.98e-04 | 199 | 37 | 4 | 222_UP | |
| Drug | Nitrofural [59-87-0]; Up 200; 20.2uM; MCF7; HT_HG-U133A | 2.98e-04 | 199 | 37 | 4 | 3320_UP | |
| Drug | Mephenytoin [50-12-4]; Up 200; 18.4uM; MCF7; HT_HG-U133A | 2.98e-04 | 199 | 37 | 4 | 3580_UP | |
| Drug | Acetazolamide [59-66-5]; Down 200; 18uM; PC3; HT_HG-U133A | 2.98e-04 | 199 | 37 | 4 | 1808_DN | |
| Drug | Xylometazoline hydrochloride [1218-35-5]; Down 200; 14.2uM; MCF7; HT_HG-U133A | 2.98e-04 | 199 | 37 | 4 | 7020_DN | |
| Drug | Serotonin hydrochloride [153-98-0]; Down 200; 18.8uM; HL60; HT_HG-U133A | 2.98e-04 | 199 | 37 | 4 | 2449_DN | |
| Drug | Griseofulvin [126-07-8]; Down 200; 11.2uM; MCF7; HT_HG-U133A | 2.98e-04 | 199 | 37 | 4 | 4687_DN | |
| Drug | WP871 | 3.04e-04 | 16 | 37 | 2 | CID000002006 | |
| Drug | Sulfamethoxazole [723-46-6]; Up 200; 15.8uM; PC3; HT_HG-U133A | 3.04e-04 | 200 | 37 | 4 | 3667_UP | |
| Drug | methenamine silver | 3.10e-04 | 201 | 37 | 4 | CID000004101 | |
| Drug | AC1OAGGW | 3.22e-04 | 203 | 37 | 4 | CID006857364 | |
| Drug | Galactosamine | 3.32e-04 | 83 | 37 | 3 | ctd:D005688 | |
| Drug | BXL628 | 3.44e-04 | 17 | 37 | 2 | ctd:C487049 | |
| Drug | formamide | 3.56e-04 | 85 | 37 | 3 | CID000000713 | |
| Drug | bumetanide | 3.59e-04 | 209 | 37 | 4 | CID000002471 | |
| Disease | autosomal dominant nonsyndromic deafness 20 (implicated_via_orthology) | 9.30e-08 | 8 | 36 | 3 | DOID:0110550 (implicated_via_orthology) | |
| Disease | Baraitser-Winter syndrome 1 (implicated_via_orthology) | 9.30e-08 | 8 | 36 | 3 | DOID:0081112 (implicated_via_orthology) | |
| Disease | Moyamoya disease (implicated_via_orthology) | 9.30e-08 | 8 | 36 | 3 | DOID:13099 (implicated_via_orthology) | |
| Disease | thoracic aortic aneurysm (implicated_via_orthology) | 9.30e-08 | 8 | 36 | 3 | DOID:14004 (implicated_via_orthology) | |
| Disease | intestinal atresia (implicated_via_orthology) | 1.99e-07 | 10 | 36 | 3 | DOID:10486 (implicated_via_orthology) | |
| Disease | patent ductus arteriosus (implicated_via_orthology) | 1.99e-07 | 10 | 36 | 3 | DOID:13832 (implicated_via_orthology) | |
| Disease | Cardiomyopathy, Dilated | 3.49e-07 | 48 | 36 | 4 | C0007193 | |
| Disease | Bombay phenotype | 1.45e-06 | 2 | 36 | 2 | cv:C1859408 | |
| Disease | BOMBAY PHENOTYPE | 1.45e-06 | 2 | 36 | 2 | 616754 | |
| Disease | infertility (implicated_via_orthology) | 3.03e-05 | 7 | 36 | 2 | DOID:5223 (implicated_via_orthology) | |
| Disease | Cardiomyopathy, Familial Idiopathic | 3.14e-05 | 50 | 36 | 3 | C1449563 | |
| Disease | Hypertrophic Cardiomyopathy | 4.66e-05 | 57 | 36 | 3 | C0007194 | |
| Disease | nicotine dependence (implicated_via_orthology) | 9.48e-05 | 12 | 36 | 2 | DOID:0050742 (implicated_via_orthology) | |
| Disease | Benign tumor of pancreas | 1.12e-04 | 13 | 36 | 2 | C0347284 | |
| Disease | Pancreatic carcinoma | 2.44e-04 | 19 | 36 | 2 | C0235974 | |
| Disease | Pancreatic Neoplasm | 2.49e-04 | 100 | 36 | 3 | C0030297 | |
| Disease | Malignant neoplasm of pancreas | 2.64e-04 | 102 | 36 | 3 | C0346647 | |
| Disease | Adenocarcinoma of prostate | 2.71e-04 | 20 | 36 | 2 | C0007112 | |
| Disease | serum carcinoembryonic antigen measurement | 2.71e-04 | 20 | 36 | 2 | EFO_0005760 | |
| Disease | BREAST CANCER | 3.00e-04 | 21 | 36 | 2 | 114480 | |
| Disease | Mammary Carcinoma, Human | 4.18e-04 | 525 | 36 | 5 | C4704874 | |
| Disease | Mammary Neoplasms, Human | 4.18e-04 | 525 | 36 | 5 | C1257931 | |
| Disease | Mammary Neoplasms | 4.25e-04 | 527 | 36 | 5 | C1458155 | |
| Disease | Left Ventricular Hypertrophy | 4.27e-04 | 25 | 36 | 2 | C0149721 | |
| Disease | Breast Carcinoma | 4.67e-04 | 538 | 36 | 5 | C0678222 | |
| Disease | Malignant tumor of breast | 4.98e-04 | 27 | 36 | 2 | cv:C0006142 | |
| Disease | Breast neoplasm | 4.98e-04 | 27 | 36 | 2 | cv:C1458155 | |
| Disease | Familial cancer of breast | 4.98e-04 | 27 | 36 | 2 | cv:C0346153 | |
| Disease | choline measurement | 5.36e-04 | 130 | 36 | 3 | EFO_0010116 | |
| Disease | Breast Cancer, Familial | 6.16e-04 | 30 | 36 | 2 | C0346153 | |
| Disease | Primary familial dilated cardiomyopathy | 6.16e-04 | 30 | 36 | 2 | cv:C0340427 | |
| Disease | cholesteryl esters to total lipids in large LDL percentage | 6.58e-04 | 31 | 36 | 2 | EFO_0022249 | |
| Disease | phospholipid measurement | 6.66e-04 | 140 | 36 | 3 | EFO_0004639 | |
| Disease | Malignant neoplasm of urinary bladder | 6.79e-04 | 141 | 36 | 3 | C0005684 | |
| Disease | neurodegenerative disease (implicated_via_orthology) | 7.37e-04 | 145 | 36 | 3 | DOID:1289 (implicated_via_orthology) | |
| Disease | Primary dilated cardiomyopathy | 7.92e-04 | 34 | 36 | 2 | cv:C0007193 | |
| Disease | low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio | 8.61e-04 | 153 | 36 | 3 | EFO_0004611, EFO_0020946 | |
| Disease | endometrial cancer (is_implicated_in) | 8.88e-04 | 36 | 36 | 2 | DOID:1380 (is_implicated_in) | |
| Disease | duodenal ulcer | 8.88e-04 | 36 | 36 | 2 | EFO_0004607 | |
| Disease | Hypercholesterolemia | 1.04e-03 | 39 | 36 | 2 | C0020443 | |
| Disease | triglyceride measurement, low density lipoprotein cholesterol measurement | 1.09e-03 | 166 | 36 | 3 | EFO_0004530, EFO_0004611 | |
| Disease | Neoplasm of uncertain or unknown behavior of breast | 1.15e-03 | 41 | 36 | 2 | C0496956 | |
| Disease | Breast adenocarcinoma | 1.15e-03 | 41 | 36 | 2 | C0858252 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| QYVDDIWLMFNNAWL | 1116 | Q09472 | |
| HWDYLLEEMQWMATD | 811 | Q96L91 | |
| WDDMEKIWHHTFYNE | 81 | P68133 | |
| WDDMEKIWHHSFYNE | 81 | P62736 | |
| LWEEERAFWMENNGH | 191 | Q6NSX1 | |
| WWNDFMVLACYNIND | 546 | Q4ADV7 | |
| ELWDLSEAWMQANYD | 461 | Q8IYF1 | |
| HLMWFERLYVWLQCF | 1176 | A6NKB5 | |
| YWVHWHMLEILGFEE | 421 | Q14999 | |
| EELHYQAAWRNMQWD | 2096 | Q13315 | |
| VTFQGNLWMWIDEHF | 141 | D3W0D1 | |
| YQLIAEFAWDWLEVH | 341 | Q9NZS9 | |
| YNHYRWIIWKLAAME | 2621 | P51587 | |
| RIPWQNYHLNDWMEE | 121 | Q10981 | |
| EDFEWTRHLQYKWNE | 1096 | Q0VDD8 | |
| LAWWEDMVAEFHDQV | 496 | P10253 | |
| RMNDLHYLNLDTWEW | 241 | Q9Y2U9 | |
| FADLHFEEGWYMWLQ | 306 | P04180 | |
| QETIYDFWRMVWHEN | 976 | P28827 | |
| WRELQLHDWMSEEYA | 141 | P19526 | |
| LQKWMEAFWQHFFDL | 381 | Q8IZC4 | |
| KDHQVCLEWNMGYIW | 216 | Q68CR1 | |
| HEALEEALQSMWFWV | 2626 | Q8NF91 | |
| LGNMEEDNWRWHFYD | 111 | P31040 | |
| NWDDMEKIWHHTFYN | 741 | P0CG39 | |
| WNDWQALMEHYSVDI | 451 | Q9P2P6 | |
| WDDMEKIWHHTFYNE | 81 | P68032 | |
| MAAHEWDWFQREELI | 1 | Q96JQ2 | |
| ANWVSEYWLNDMYLN | 191 | P28329 | |
| TMTIDWNEWRDYHLL | 131 | Q6KCM7 | |
| HLCYWELMWINVFQQ | 431 | Q5VTQ0 | |
| DMEEMYLFHIWGQRW | 516 | Q6UWL2 | |
| HRQAFAWVDEWYDMT | 216 | Q9UKF7 | |
| QWALLMQGWFHFLQD | 101 | Q9UBD6 | |
| MTIDWQEWRDHFLLH | 131 | Q9BV35 | |
| GFTEYIHDWWNLMDF | 426 | Q9UL62 | |
| LQDYIHDWWNLMDFV | 426 | Q9UBN4 | |
| MWFAAFQTYEHNDWI | 466 | Q96S06 |